High-dose chemotherapy and autologous bone marrow transplantation for relapsed and refractory Hodgkin's disease

1992 ◽  
Vol 28 (8-9) ◽  
pp. 1396-1400 ◽  
Author(s):  
M. Harding ◽  
P. Selby ◽  
M. Gore ◽  
T. Perren ◽  
J. Treleavan ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Hodgkin's Disease ◽  
Marrow Transplantation ◽  
Hodgkin’S Disease ◽  
Autologous Bone Marrow Transplantation ◽  
Autologous Bone Marrow ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Autologous Bone

scholarly journals High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease

1986 ◽  
Vol 53 (6) ◽  
pp. 737-742 ◽  
Author(s):  
T Philip ◽  
J Dumont ◽  
F Teillet ◽  
D Maraninchi ◽  
N C Gorin ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Hodgkin's Disease ◽  
Marrow Transplantation ◽  
Hodgkin’S Disease ◽  
Autologous Bone Marrow Transplantation ◽  
Autologous Bone Marrow ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Autologous Bone

Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.

1989 ◽  
Vol 7 (2) ◽  
pp. 179-185 ◽  
Author(s):  
S Jagannath ◽  
J O Armitage ◽  
K A Dicke ◽  
S L Tucker ◽  
W S Velasquez ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Hodgkin's Disease ◽  
Marrow Transplantation ◽  
Hodgkin’S Disease ◽  
Autologous Bone Marrow Transplantation ◽  
Significant Proportion ◽  
Autologous Bone Marrow ◽  
High Dose ◽  
Autologous Bone

Sixty-one patients with relapsed Hodgkin's disease who had failed a mechlorethamine, vincristine, procarbazine, and prednisone (MOPP)- and a doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)-like regimen were treated with a high-dose combination chemotherapy containing cyclophosphamide, carmustine, and etoposide (CBV) and autologous bone marrow transplantation (ABMT). Fifty-nine patients were treated in relapse and two were intensified early in third remission. Following therapy, 29 patients (47%) were in complete remission (CR), 18 patients (30%) achieved a partial response (PR), and 14 patients (23%) had progressive disease (PD). Among the partial responders, six patients achieved a CR following addition of local radiation therapy to sites of residual nodal disease. For a minimum follow-up of 2 years, 23 patients (38%) are alive and free of disease. High-dose CBV therapy produced severe myelosuppression, and there were four (7%) treatment-related deaths. A multivariate analysis identified failure of more than two prior chemotherapy treatments and poor performance status as important adverse risk factors for survival. Patients who had no adverse risk factor and/or were intensified with CBV while Hodgkin's disease was still responding to conventional chemotherapy, had a CR rate of 63%, with 77% projected 3-year survival; whereas, all other patients had a CR rate of 31%, and a projected 3-year survival of only 18%. Our results demonstrated that CBV and ABMT can induce remission duration of 2 years or greater in a significant proportion of patients with relapsed Hodgkin's disease.

High dose chemotherapy and autologous bone marrow transplantation in advanced Hodgkin's disease

1992 ◽  
Vol 157 (8) ◽  
pp. 527-530
Author(s):  
Marianne J Morgan ◽  
Anthony J Dodds ◽  
Kathryn Downs ◽  
Max Wolf ◽  
Henry Januszewicz ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Hodgkin’S Disease ◽  
Autologous Bone Marrow Transplantation ◽  
Autologous Bone Marrow ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Autologous Bone ◽  
Advanced Hodgkin’S Disease
Sign in / Sign up

Export Citation Format

Share Document